Antiviral Approach to Cytomegalovirus Infection: An Overview of Conventional and Novel Strategies
Open Access
- 22 September 2023
- journal article
- review article
- Published by MDPI AG in Microorganisms
- Vol. 11 (10) , 2372
Abstract
Human cytomegalovirus (HCMV) is a herpesvirus capable of establishing a lifelong persistence in the host through a chronic state of infection and remains an essential global concern due to its distinct life cycle, mutations, and latency. It represents a life-threatening pathogen for immunocompromised patients, such as solid organ transplanted patients, HIV-positive individuals, and hematopoietic stem cell recipients. Multiple antiviral approaches are currently available and administered in order to prevent or manage viral infections in the early stages. However, limitations due to side effects and the onset of antidrug resistance are a hurdle to their efficacy, especially for long-term therapies. Novel antiviral molecules, together with innovative approaches (e.g., genetic editing and RNA interference) are currently in study, with promising results performed in vitro and in vivo. Since HCMV is a virus able to establish latent infection, with a consequential risk of reactivation, infection management could benefit from preventive treatment for critical patients, such as immunocompromised individuals and seronegative pregnant women. This review will provide an overview of conventional antiviral clinical approaches and their mechanisms of action. Additionally, an overview of proposed and developing new molecules is provided, including nucleic-acid-based therapies and immune-mediated approaches.Keywords
Funding Information
- EU Funding within the MUR PNRR Extended Partnership Initiative on Emerging Infectious Diseases (PE00000007)
This publication has 150 references indexed in Scilit:
- Performance of the QuantiFERON-Cytomegalovirus (CMV) Assay for Detection and Estimation of the Magnitude and Functionality of the CMV-Specific Gamma Interferon-Producing CD8+T-Cell Response in Allogeneic Stem Cell Transplant RecipientsClinical and Vaccine Immunology, 2012
- Diagnostic Consequences of Cytomegalovirus Glycoprotein B PolymorphismsJournal of Clinical Microbiology, 2011
- The Human Cytomegalovirus Gene Products Essential for Late Viral Gene Expression Assemble into Prereplication Complexes before Viral DNA ReplicationJournal of Virology, 2011
- Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trialThe Lancet, 2011
- In Vitro and In Vivo Activities of the Novel Anticytomegalovirus Compound AIC246Antimicrobial Agents and Chemotherapy, 2010
- Origins and Mechanisms of miRNAs and siRNAsCell, 2009
- Immunobiology of Human Cytomegalovirus: from Bench to BedsideClinical Microbiology Reviews, 2009
- Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleasesNature Biotechnology, 2008
- Exon 4 of the Human Cytomegalovirus (CMV) Major Immediate-Early Gene as a Target for CMV Real-Time PCRJournal of Clinical Microbiology, 2008
- RNA interferenceNature, 2002